Hemorrhage from other sites in respiratory passages R04. 89 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM R04. 89 became effective on October 1, 2021.
Bleeding into the lungs (pulmonary haemorrhage) occurs mainly in infants born before term (37 weeks' gestation) because of severe lung disease (particularly respiratory distress syndrome, a disease caused by the lack of the normal lining chemicals of the lung (surfactant)) and the need for a breathing machine (assisted ...
Pulmonary hemorrhage is the extravasation of blood into the alveoli, that is, bleeding into the lower respiratory tract. It can be severe and life-threatening.[1] In diffuse alveolar hemorrhage (DAH), the bleeding is usually of sudden onset, and is widespread and not limited to a section of the lungs.
Diffuse alveolar hemorrhage (DAH) is a life-threatening condition caused by a variety of disorders associated with hemoptysis, anemia, diffuse lung infiltration, and acute respiratory failure.
Results Pulmonary hemorrhage occurred in 5.7% of the total population of very low-birth-weight infants. Despite similar severity of lung disease, significantly more infants who developed pulmonary hemorrhage received surfactant therapy compared with controls (91% vs 69%, P=. 005).
The usual causes for pulmonary hemorrhage in children include infections, cystic fibrosis, bronchiectasis, foreign bodies, trauma, immunologic disease, neoplasms, pulmonary hemosiderosis, and congenital cardiovascular lesions.
Pulmonary hemorrhage, also referred to as massive hemoptysis, is a potentially life-threatening condition involving bleeding from the pulmonary or bronchial vasculature which is usually due to higher pressure of the bronchial system.
Localized pulmonary bleeding usually requires local treatment, like bronchoscopic therapy, bronchial artery embolization or surgery. Diffuse alveolar haemorrhage must be treated systemically, i. e. by immunosuppressive therapy in cases of vasculitis or by medical treatment of coagulation disorders.
Bronchoscopy is the key investigation needed to diagnose DAH by lavage and to exclude other associated infections. Bronchoscopy has higher yield if performed within the first 48 h. Persistent or increasing blood on three sequential lavage aliquots from one affected area of lung supports the diagnosis of DAH [36].
Diffuse alveolar damage (DAD) is a stereotyped response to injury in lung tissue. DAD consists of an intra-alveolar exudate (often described as hyaline membrane) in association with marked hyperplasia of type II pneumocytes that may appear cytologically bizarre and pleomorphic (Fig. 8-2).
Localized pulmonary bleeding usually requires local treatment, like bronchoscopic therapy, bronchial artery embolization or surgery. Diffuse alveolar haemorrhage must be treated systemically, i. e. by immunosuppressive therapy in cases of vasculitis or by medical treatment of coagulation disorders.
Pulmonary hemorrhage has a high mortality rate of 30% to 40%.
On one hand, pulmonary hemorrhage is thought to be a complication of surfactant therapy because surfactant can rapidly lower the intrapulmonary pressure, which facilitates left to right shunting through PDA and an increase in pulmonary blood flow.
Pulmonary hemosiderosis is associated with rheumatoid arthritis, thyrotoxicosis, celiac disease, and autoimmune hemolytic anemia, suggesting a potential autoimmune mechanism.